SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia
SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia
复制标题
SH3BGRL 作为一种新型预后生物标志物在急性髓系白血病中下调
DOI:
10.1080/10428194.2017.1344843
复制
发表时间:
2018-04
影响因子:
2.6
通讯作者:
王海河
中科院分区:
文献类型:
--
作者:
Limei Xu;Mingming Zhang;Hui Li;Wen Guan;Bin Liu;Fengqi Liu;Shulan Yang;Xiuzheng Tong;王海河
Abstract Phosphatase PRL-3 expression is positively associated to acute myeloid leukemia (AML) progression and drug resistance. SH3-domain-binding glutamic acid-rich protein-like protein (SH3BGRL), a downstream effector of PRL-3, plays a tumor suppressive role in solid tumors, but it remains elusive in AML. Here, we followed up and validated the relevance of SH3BGRL expression to AML progression in 116 cases. Results showed that SH3BGRL is down-regulated in 62.37% AML cases with poor prognosis. Cases with positive response to therapy accompanies with SH3GRL expression restoration. Mechanistically, SH3BGRL down-regulation promotes AML cell cycle progression and enhances the anti-apoptotic ability to drug cytotoxicity. While ectopic SH3BGRL blocks AML cell cycle and proliferation to sensitize them to therapeutic drugs via apoptosis. Xenograft assays further confirmed the suppressive role of SH3BGRL in leukemogenesis. Thus, our results demonstrated that SH3BGRL is a novel crucial player in AML progression and could be both a potential diagnostic and prognostic marker.
登录
查看更多内容
影响因子:
4.2
作者:
Xiong J;Li Z;Zhang Y;Li D;Zhang G;Luo X;Jie Z;Liu Y;Cao Y;Le Z;Tan S;Zou W;Gong P;Qiu L;Li Y;Wang H;Chen H
通讯作者:
Chen H
影响因子:
3.9
作者:
Yohe S
通讯作者:
Yohe S
影响因子:
2.6
作者:
Egeo, A;Di Lisi, R;Scartezzini, P
通讯作者:
Scartezzini, P
影响因子:
3.5
作者:
J. Orozco;F. Appelbaum
通讯作者:
J. Orozco;F. Appelbaum
DOI:
10.1182/hem.v13.5.6435
发表时间:
2016-09
期刊:
--
影响因子:
--
作者:
P. Moss
通讯作者:
P. Moss